{"filings":[{"id":70081,"accession_number":"0001193125-26-221857","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-05-13T20:54:51+00:00","items":["5.07"],"status":"ready","headline":"Core Labs shareholders re-elect directors, ratify auditor, approve say-on-pay at May 12 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Harvey Klingensmith (35.9M for, 3.8M withheld) and Curtis Anastasio (39.3M for, 0.4M withheld) as Class I directors.","Ratified KPMG as independent auditor for FY 2026 with 41.2M for, 0.5M against.","Advisory vote on named executive officer compensation approved: 38.3M for, 1.3M against, 0.1M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96922,"accession_number":"0001193125-26-192018","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q1 revenue $121.8M; GAAP EPS -$0.02, ex-items $0.06","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $121.8M, down 12% sequentially and flat year-over-year.","GAAP operating income $1.9M; ex-items $6.6M, down 58% sequentially.","GAAP loss per share $0.02; EPS ex-items $0.06, down 72% sequentially and 58% YoY.","Free cash flow $0.5M; net debt up $3.9M; leverage ratio 1.20.","Q2 dividend $0.01/sh, record May 11, payable June 1; repurchased 51,781 shares for $0.9M."],"consensus_eps_estimate":0.1094,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":121797000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111293,"accession_number":"0001193125-26-119934","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Core Labs cuts Q1 2026 guidance citing Middle East conflict; revenue now $119-123M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First quarter 2026 revenue guidance revised to $119M-$123M, down from previously issued guidance.","Operating income ex-items projected at $5.7M-$7.1M; EPS ex-items $0.05-$0.07.","Client-driven project delays, travel constraints, and supply-chain disruptions from Middle East conflict cited.","Reservoir Description segment most impacted; Production Enhancement less affected but energetics shipments delayed.","Earnings call scheduled for April 30, 2026; press release on April 29 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111290,"accession_number":"0001193125-26-109251","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K/A","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Core Laboratories corrects Q4/FY2025 tax error; net income down $4.2M, EPS down $0.09","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Income tax expense understated by $4.2M in Q4 and FY2025 due to tax reconciliation and fire-related insurance gain timing.","Net income reduced by $4.2M; diluted EPS reduced by $0.09 for both Q4 and full year 2025.","Revenue, operating income, and cash from operations unchanged.","Also corrected immaterial 2024 balance sheet errors: $4.7M misclassification and $5.6M write-off of unrecoverable tax receivable.","Revised financials expected in 10-K filing on or around March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111292,"accession_number":"0001193125-26-093962","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Core Laboratories lowers shareholder voting threshold to simple majority for mergers and change-in-control","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment reducing supermajority voting requirement from 66-2/3% to simple majority for certain shareholder actions including mergers and change-in-control.","Amendment effective February 27, 2026; affects Section 2.11 of the First Amended and Restated Bylaws.","Only change in the amended bylaws; no other governance provisions modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111291,"accession_number":"0001193125-26-037789","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q4 rev $138.3M (+7% YoY); ex-items EPS $0.21 (-4%); declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $138.3M (+7% YoY); GAAP EPS $0.15, ex-items $0.21 (-4% YoY).","Q4 op. income ex-items $15.7M (11% margin, -80bps YoY); free cash flow $5.1M.","FY 2025 revenue $526.5M (flat); GAAP EPS $0.68 (+3%), ex-items $0.75 (-14%).","Net debt reduced $18.7M in 2025 (17%); leverage ratio improved to 1.09x.","Declared Q1 2026 dividend $0.01/sh, payable Mar 9, record Feb 16; repurchased 1.2M shares."],"consensus_eps_estimate":0.1906,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":526520000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127901,"accession_number":"0001193125-25-246793","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q3 rev $134.5M flat YoY; ex-items EPS $0.22, down 12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.5M, up 3% sequentially but flat YoY.","GAAP EPS $0.30; ex-items EPS $0.22 (+16% seq, -12% YoY).","Ex-items operating margins 12%, up 120 bps seq; incremental margins 48%.","Repurchased 462,248 shares for $5.0M; net debt reduced $3.4M; leverage 1.10x.","Quarterly dividend $0.01/sh, record Nov 3, payable Nov 24."],"consensus_eps_estimate":0.1949,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":388265000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144671,"accession_number":"0000950170-25-097897","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Core Lab Q2 rev $130.2M (+5% seq, flat YoY); ex-items EPS $0.19; free cash flow $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $130.2M (+5% sequentially, flat YoY); GAAP EPS $0.22; ex-items EPS $0.19 (-14% YoY, +33% sequentially).","Ex-items operating income $14.5M, margins 11% (+160 bps seq); incremental margins 41%.","Free cash flow $10.4M (+160% seq); net debt reduced $9.1M; leverage ratio improved to 1.27x.","Company repurchased 237,632 shares for $2.7M in Q2.","Credit facility amended: commitments raised to $150M from $135M, maturity extended to July 2029, $50M accordion."],"consensus_eps_estimate":0.1906,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":253744000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163069,"accession_number":"0000950170-25-077738","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Core Labs elects three Class II directors, ratifies KPMG, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Martha Z. Carnes, Katherine Murray, and Rob Martinovich as Class II directors to serve until 2028.","Ratified KPMG as independent auditor for 2025 with 41.8M votes for, 0.7M against.","Advisory vote on executive compensation approved with 38.0M for, 2.3M against, 26.5K abstentions.","All proposals passed with required majorities; broker non-votes were 2.18M on director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163068,"accession_number":"0000950170-25-057483","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q1 rev $123.6M, ex-items EPS $0.14 down 25% YoY, declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $123.6M, down 4% sequentially and 5% YoY; GAAP EPS $0.00, ex-items EPS $0.14 (down 25% YoY).","Operating income ex-items $11.8M, margins 10%; free cash flow $3.9M, up >50% YoY.","Net debt reduced $4.9M, leverage ratio 1.31; repurchased 131,598 shares for $2.0M.","Declares $0.01 quarterly dividend, record May 5, payable May 27."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":123585000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180979,"accession_number":"0000950170-25-010552","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q4 revenue $129.2M, EPS $0.15; FY revenue $523.8M up 3%, free cash flow $43.4M up 200%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $129.2M (down 4% sequentially, up slightly YoY); GAAP EPS $0.15; ex-items EPS $0.22 (down 12% sequentially, up 16% YoY).","Q4 operating income ex-items $15.7M (down 14% sequentially, up 4% YoY) with margins of 12%.","Q4 free cash flow $16.2M (up over 50% sequentially); net debt reduced $11.7M; leverage ratio 1.31.","FY 2024 revenue $523.8M (up 3%); ex-items operating income $65.3M (up 7%); ex-items EPS $0.87 (up 9%).","Company repurchased 264,982 shares for $4.9M in Q4; declared $0.01/share dividend payable March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":523848000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197853,"accession_number":"0000950170-24-116676","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q3 revenue $134.4M +7% YoY; EPS ex-items $0.25 +14% YoY; net debt reduced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.4M, up 3% sequentially and over 7% year-over-year.","Operating income ex-items $18.2M, up 11% sequentially and 14% YoY; margins 14%.","GAAP EPS $0.25; ex-items $0.25, up 14% sequentially and YoY.","Free cash flow $10.4M; net debt reduced $11.8M; debt leverage ratio 1.47.","Declares Q4 dividend $0.01/share, payable Nov 25 to holders of record Nov 4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":394611000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214038,"accession_number":"0000950170-24-086092","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q2 revenue $130.6M; GAAP EPS $0.19, ex-items $0.22; cuts net debt $15.8M; declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $130.6M, up slightly sequentially and YoY; operating income GAAP $16.0M, ex-items $16.4M (+10% sequentially, +5% YoY).","GAAP EPS $0.19; ex-items EPS $0.22, up 16% sequentially and 5% YoY.","Free cash flow $14.3M; net debt reduced by $15.8M during Q2 2024.","Declares Q3 2024 dividend of $0.01/share, payable Aug 26, record Aug 5, 2024.","Operating margins ex-items reached 13%, expanding over 100 bps sequentially."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":260214000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233258,"accession_number":"0000950170-24-057934","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting results: all four proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors Lawrence Bruno and Kwaku Temeng re-elected with 37.4M and 33.0M votes for respectively.","Ratification of KPMG as auditor for FY2024 approved: 40.4M for, 0.8M against.","Advisory vote on executive compensation passed: 36.4M for, 1.8M against.","Amendment to 2020 Long-Term Incentive Plan (increase shares, extend to 2034) approved: 36.7M for, 1.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233257,"accession_number":"0000950170-24-047646","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Laboratories Q1 2024: Revenue $129.6M, EPS ex-items $0.19; declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $129.6M, up modestly sequentially and YoY.","GAAP operating income $8.6M; ex-items $14.9M, up 3% YoY.","GAAP EPS $0.07; ex-items $0.19, flat YoY.","Free cash flow $2.5M in Q1.","Declares $0.01 dividend payable May 28, record May 6."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":129637000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}